169 related articles for article (PubMed ID: 23860531)
21. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
22. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
[TBL] [Abstract][Full Text] [Related]
25. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
Kumar V; Ailawadhi S; Bojanini L; Mehta A; Biswas S; Sher T; Roy V; Vishnu P; Marin-Acevedo J; Alegria VR; Paulus A; Aulakh S; Iqbal M; Manochakian R; Tan W; Chanan-Khan A; Ailawadhi M
Blood Cancer J; 2019 Sep; 9(10):75. PubMed ID: 31570695
[TBL] [Abstract][Full Text] [Related]
26. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.
Brewer JD; Shanafelt TD; Khezri F; Sosa Seda IM; Zubair AS; Baum CL; Arpey CJ; Cerhan JR; Call TG; Roenigk RK; Smith CY; Weaver AL; Otley CC
J Am Acad Dermatol; 2015 Feb; 72(2):302-9. PubMed ID: 25479909
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
28. Composite Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Clinicopathological Study of Six Cases.
Jelloul FZ; Chen QH; Yang T; Haghi N; Brody J; Zhang X; Sheikh-Fayyaz S
Int J Surg Pathol; 2018 Apr; 26(2):135-144. PubMed ID: 29069998
[TBL] [Abstract][Full Text] [Related]
29. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
32. Occurrence of second neoplasms in chronic lymphocytic leukemia. Experience at Padua Hospital between 1979 and 1991.
Bertoldero G; Scribano G; Podda L; Berti R; Amadori G
Ann Hematol; 1994 Oct; 69(4):195-8. PubMed ID: 7948306
[TBL] [Abstract][Full Text] [Related]
33. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia.
Mansfield AS; Rabe KG; Slager SL; Schwager SM; Call TG; Brewer JD; Shanafelt TD
J Oncol Pract; 2014 Jan; 10(1):e1-4. PubMed ID: 23981385
[TBL] [Abstract][Full Text] [Related]
34. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Patel K; Danilov AV; Pagel JM
Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
[TBL] [Abstract][Full Text] [Related]
35. An increased risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia in US patients with Merkel cell carcinoma versus Australian patients: A clinical clue to a different mechanism of pathogenesis?
Bloom R; Amber KT; Nouri K
Australas J Dermatol; 2016 Aug; 57(3):e114-6. PubMed ID: 25801041
[TBL] [Abstract][Full Text] [Related]
36. Risk of second cancer after chronic lymphocytic leukemia.
Schöllkopf C; Rosendahl D; Rostgaard K; Pipper C; Hjalgrim H
Int J Cancer; 2007 Jul; 121(1):151-6. PubMed ID: 17351903
[TBL] [Abstract][Full Text] [Related]
37. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.
Dasanu CA; Alexandrescu DT
MedGenMed; 2007 Nov; 9(4):35. PubMed ID: 18311385
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
40. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
